ABL DiagnosticsXPAR:ABLD +0.76%51 FCF Yield % is 1.67 as of Jul. 06, 2026. GuruFocus rates XPAR:ABLD with a GF Score™ of 51/100 and a GF Value™ of €7.71 (Significantly Undervalued). The stock has 4 warning signs investors should review. Among 681 Healthcare Providers & Services companies, ABL Diagnostics ranks worse than 50.66% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
The historical rank and industry rank for ABL Diagnostics's FCF Yield % or its related term are showing as below:
XPAR:ABLD'
s FCF Yield % Range Over the Past 10 Years
Min: -22.01 Med: -6.97 Max: 8.11
Current: 1.67
During the past 13 years, the highest FCF Yield % of ABL Diagnostics was 8.11%. The lowest was -22.01%. And the median was -6.97%.
XPAR:ABLD's FCF Yield % is ranked worse than 50.66% of 681
companies
in the Healthcare Providers & Services industry
Industry Median: 1.83
vs XPAR:ABLD: 1.67
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
ABL Diagnostics FCF Yield % Related Terms
ABL Diagnostics FCF Yield % Historical Data
* Premium members only.
The historical data trend for ABL Diagnostics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XPAR:ABLD vs VEEV, BTSG, TEM: FCF Yield % Comparison
For the Health Information Services subindustry, ABL Diagnostics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
ABL Diagnostics FCF Yield % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, ABL Diagnostics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where ABL Diagnostics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ABL Diagnostics (XPAR:ABLD) has a FCF Yield % of 1.67 as of Jul. 06, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on ABL Diagnostics and its competitors. According to the industry distribution chart, ABL Diagnostics ranks #345 out of 681 companies in the Healthcare Providers & Services industry, placing it in the top 50.7%.
Is ABL Diagnostics' FCF Yield % too high?
ABL Diagnostics' current FCF Yield % is 1.67. The Healthcare Providers & Services industry median FCF Yield % is 1.83. ABL Diagnostics' value of 1.67 is 8.7% below this industry median. Based on the distribution chart, ABL Diagnostics ranks #345 out of 681 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, ABL Diagnostics has a GF Score™ of 51/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does ABL Diagnostics' FCF Yield % compare to VEEV and BTSG?
According to the Healthcare Providers & Services industry distribution chart, ABL Diagnostics ranks #345 out of 681 companies for FCF Yield %. This places ABL Diagnostics in the lower half of its industry. The industry median FCF Yield % is 1.83. ABL Diagnostics' value of 1.67 is 8.7% below this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Healthcare Providers & Services company?
The median FCF Yield % among Healthcare Providers & Services companies is 1.83, based on 681 companies in the industry. Companies in the top quartile (top 25%) have a FCF Yield % significantly above this median, while those in the bottom quartile fall well below. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. ABL Diagnostics's current FCF Yield % of 1.67 is 8.7% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on ABL Diagnostics and its competitors. For the Healthcare Providers & Services industry, the median FCF Yield % is 1.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. ABL Diagnostics's current FCF Yield % is 1.67. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ABL Diagnostics stock overvalued right now?
Based on GuruFocus' analysis, ABL Diagnostics (XPAR:ABLD) is currently considered Significantly Undervalued. The stock's GF Value™ is €7.71, compared to a current price of €2.66 — trading 65.5% below its estimated fair value. The current FCF Yield % is 1.67 and 8.7% below the Healthcare Providers & Services industry median of 1.83. ABL Diagnostics' overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For ABL Diagnostics (XPAR:ABLD), the current FCF Yield % is 1.67 as of Jul. 06, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ABL Diagnostics (XPAR:ABLD) Overvalued in 2026?
Based on GuruFocus' analysis, ABL Diagnostics stock appears to be undervalued.
The current stock price of €2.66 is trading 65.5% below its estimated GF Value™ of €7.71.
GuruFocus considers ABL Diagnostics to be Significantly Undervalued.
Key valuation signals for XPAR:ABLD:
FCF Yield %: 1.67
GF Value™: €7.71 vs. price of €2.66 (65.5% below fair value)
Industry Position: 8.7% below the Healthcare Providers & Services median (#345 of 681)
No single metric tells the full story. See the XPAR:ABLD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ABL Diagnostics is a diagnostic and medical software company. The group has focused on the development of software for collecting and processing medical databases, measuring the quality of care, diagnosing infectious diseases by genotyping, and providing decision support for doctors and nurses, virology and microbiology laboratories, and researchers dealing with patients suffering from chronic and complex diseases. It also develops, manufactures, and markets kits for clinical specimen collection.
51GF Score
Get the complete analysis for XPAR:ABLD
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XPAR:ABLD has been successfully added to your 
